ArrowMark Colorado Holdings’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,806,712
| Closed | -$78.2M | – | 373 |
|
|
2021
Q3 | $78.2M | Sell |
2,806,712
-73,407
| -3% | -$2.09M | 0.61% | 50 |
|
|
2021
Q2 | $85.4M | Sell |
2,880,119
-283,136
| -9% | -$8.17M | 0.64% | 53 |
|
|
2021
Q1 | $88.4M | Buy |
3,163,255
+199,120
| +7% | +$5.51M | 0.66% | 47 |
|
|
2020
Q4 | $84M | Buy |
2,964,135
+201,329
| +7% | +$5.21M | 0.65% | 55 |
|
|
2020
Q3 | $69.5M | Sell |
2,762,806
-816,905
| -23% | -$21.4M | 0.66% | 50 |
|
|
2020
Q2 | $87.4M | Sell |
3,579,711
-210,937
| -6% | -$4.16M | 0.9% | 35 |
|
|
2020
Q1 | $56.1M | Sell |
3,790,648
-1,049,988
| -22% | -$21.7M | 0.74% | 45 |
|
|
2019
Q4 | $78.6M | Buy |
4,840,636
+8,983
| +0.2% | +$139K | 0.7% | 51 |
|
|
2019
Q3 | $62.8M | Buy |
4,831,653
+520,657
| +12% | +$6.37M | 0.63% | 57 |
|
|
2019
Q2 | $55.9M | Buy |
4,310,996
+901,779
| +26% | +$11.4M | 0.54% | 68 |
|
|
2019
Q1 | $53.7M | Buy |
3,409,217
+1,098,314
| +48% | +$19M | 0.51% | 65 |
|
|
2018
Q4 | $46.5M | Buy |
2,310,903
+67,248
| +3% | +$1.48M | 0.49% | 67 |
|
|
2018
Q3 | $55.8M | Buy |
2,243,655
+439,380
| +24% | +$11.9M | 0.47% | 71 |
|
|
2018
Q2 | $49.5M | Buy |
1,804,275
+68,576
| +4% | +$2.06M | 0.45% | 80 |
|
|
2018
Q1 | $53.5M | Sell |
1,735,699
-1,035
| -0.1% | -$33.3K | 0.53% | 67 |
|
|
2017
Q4 | $62.1M | Sell |
1,736,734
-398,787
| -19% | -$11.5M | 0.63% | 58 |
|
|
2017
Q3 | $58.8M | Buy |
2,135,521
+89,659
| +4% | +$2.17M | 0.67% | 52 |
|
|
2017
Q2 | $54M | Buy |
2,045,862
+119,000
| +6% | +$2.65M | 0.67% | 54 |
|
|
2017
Q1 | $40.1M | Sell |
1,926,862
-91,867
| -5% | -$1.89M | 0.55% | 63 |
|
|
2016
Q4 | $41.8M | Buy |
2,018,729
+195,515
| +11% | +$3.27M | 0.66% | 50 |
|
|
2016
Q3 | $29.6M | Buy |
1,823,214
+153,222
| +9% | +$2.22M | 0.54% | 65 |
|
|
2016
Q2 | $22.7M | Buy |
1,669,992
+535,196
| +47% | +$9.46M | 0.46% | 75 |
|
|
2016
Q1 | $19.8M | Buy |
1,134,796
+546,150
| +93% | +$11.1M | 0.44% | 79 |
|
|
2015
Q4 | $20.1M | Buy |
588,646
+575
| +0.1% | +$19.9K | 0.55% | 59 |
|
|
2015
Q3 | $17.5M | Buy |
588,071
+35,099
| +6% | +$1.07M | 0.48% | 65 |
|
|
2015
Q2 | $17.7M | Sell |
552,972
-280,800
| -34% | -$7.22M | 0.43% | 67 |
|
|
2015
Q1 | $17.3M | Buy |
833,772
+45,849
| +6% | +$792K | 0.45% | 70 |
|
|
2014
Q4 | $13.3M | Buy |
787,923
+85,373
| +12% | +$1.49M | 0.34% | 87 |
|
|
2014
Q3 | $13.6M | Buy |
702,550
+269,093
| +62% | +$7.01M | 0.37% | 90 |
|
|
2014
Q2 | $14.7M | Buy |
433,457
+413,930
| +2,120% | +$13M | 0.42% | 89 |
|
|
2014
Q1 | $615K | Buy |
+19,527
| New | +$610K | 0.02% | 228 |
|
Other funds holding RVNC
PAI
HM
ArrowMark Colorado Holdings's RVNC Position: Q4 2021 in Review
ArrowMark Colorado Holdings sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 2,806,712 shares — an estimated $78.2M sold.
ArrowMark Colorado Holdings first reported a position in RVNC in Q1 2014 and held it in 31 quarters. The position peaked at $88.4M in Q1 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.
- ArrowMark Colorado Holdings reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- ArrowMark Colorado Holdings sold 2,806,712 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $78.2M.
- ArrowMark Colorado Holdings first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
- ArrowMark Colorado Holdings's Revance Therapeutics, Inc. position peaked at $88.4M in Q1 2021.
- 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.
Based on ArrowMark Colorado Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.